Core Insights - Southbound funds increased their holdings in Baize Medical (02609.HK) by 384,600 shares on October 15, 2025, marking a net increase of 2,892,600 shares over the last five trading days [1] - Over the past 20 trading days, Baize Medical has seen a total net increase of 67,140,600 shares from southbound funds, with 16 days of net buying activity [1] - As of now, southbound funds hold 67,140,600 shares of Baize Medical, representing 5.08% of the company's total issued ordinary shares [1] Trading Data Summary - On October 15, 2025, total shares held reached 67,140,600 with a change of 384,600 shares, reflecting a 0.58% increase [2] - On October 14, 2025, total shares held were 66,756,000 with a change of 180,000 shares, a 0.27% increase [2] - On October 13, 2025, total shares held were 66,576,000 with a change of 897,600 shares, a 1.37% increase [2] - On October 3, 2025, total shares held were 65,678,400 with a change of 1,597,200 shares, a 2.49% increase [2] - On October 2, 2025, total shares held were 64,081,200 with a change of -166,800 shares, a -0.26% decrease [2] Company Overview - Baize Medical Group primarily engages in investment and provision of medical-related services, focusing on oncology [2] - The company offers comprehensive oncology medical services, including screening, diagnosis, treatment, and rehabilitation [2] - Key business areas include hospital operations, hospital management services, supply of pharmaceuticals, medical devices, and consumables [2] - Services provided encompass cancer diagnosis, treatment, rehabilitation, and end-of-life care, as well as early cancer screening, cancer vaccination, and health management for other potential health populations [2] - The company primarily operates in the Chinese market [2]

Group 1 - Mr. Fan Kunkun has submitted his resignation as the co-secretary of the company, effective from October 14, 2025 [1] - Following Mr. Fan's resignation, Mr. Yao Le has been appointed as the co-secretary, effective from October 14, 2025 [1] - Ms. Chen Shiting has submitted her resignation as (i) co-secretary; (ii) authorized representative under the Hong Kong Stock Exchange Listing Rules Section 3.05; and (iii) representative for receiving legal documents and notices in Hong Kong, effective from October 14, 2025 [1] Group 2 - After Ms. Chen's resignation, Ms. Fang Xilin has been appointed as co-secretary, authorized representative, and legal document agent, effective from October 14, 2025 [1] - Mr. Zhao Yongkai will continue to serve as another authorized representative [1]

Group 1 - Mr. Fan Kunkun has submitted his resignation as the co-secretary of the company, effective from October 14, 2025 [1] - Mr. Yao Le has been appointed as the co-secretary of the company, effective from October 14, 2025 [1] - Ms. Chen Shiting has submitted her resignation as (i) co-secretary; (ii) authorized representative under the Hong Kong Stock Exchange Listing Rules Section 3.05; and (iii) representative for receiving legal documents and notices in Hong Kong, effective from October 14, 2025 [1] - Ms. Fang Xilin has been appointed as co-secretary, authorized representative, and legal document agent, effective from October 14, 2025 [1] - Mr. Zhao Yongkai will continue to serve as another authorized representative [1]

Core Viewpoint - Baize Medical (02609.HK) announced the resignation of its co-secretary, Fan Kunkun, effective from October 14, 2025 [1] Group 1: Management Changes - Chen Shiting has submitted her resignation as (i) co-secretary; (ii) authorized representative under the Hong Kong Stock Exchange Listing Rules Section 3.05; and (iii) representative for receiving legal documents and notices in Hong Kong, effective from October 14, 2025 [1] - Fang Xilin has been appointed as co-secretary, authorized representative, and agent for legal documents, effective from October 14, 2025 [1] - Zhao Yongkai will continue to serve as another authorized representative [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任 何 損 失 承 擔 任 何 責 任。 Bayzed Health Group Inc 佰澤醫療集團 （根據開曼群島法律註冊成立的有限公司） （股份代號：2609） 聯 席 公 司 秘 書、授 權 代 表 及 法 律 程 序 文 件 代 理 人 變 更； 及 豁免嚴格遵守上市規則第3.28條及第8.17條 聯 席 公 司 秘 書、授 權 代 表 及 法 律 程 序 文 件 代 理 人 變 更 佰 澤 醫 療 集 團（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」）董 事（「董 事」）會 （「董事會」）謹 此 宣 佈，范 坤 坤 先 生（「范先生」）已 提 呈 辭 任 本 公 司 聯 席 公 司 秘 書（「聯席公司秘書」），自2025年10月14日 起 生 效。 范 先 生 確 認 彼 與 董 事 會 並 無 意 見 分 歧，亦 無 有 關 彼 辭 任 之 事 宜 須 ...

Core Insights - The article presents a ranking of 33 Hong Kong-listed medical service companies based on their stock price performance as of September 30, 2025, highlighting significant price increases and declines among these companies [1][2]. Group 1: Top Performers - The top performer is Brainstorm Cell Therapeutics (脑动极光-B) with a stock price of HKD 8.58, reflecting a remarkable increase of 166.46% [1]. - MediWound (麦迪卫康) ranks second with a stock price of HKD 1.23, showing a growth of 136.54% [1]. - Yonghe Medical (雍禾医疗) comes in third with a stock price of HKD 2.05, marking a rise of 127.78% [1]. Group 2: Notable Declines - The company with the largest decline is Yimeng Group (云康集团), with a stock price of HKD 1.28, experiencing a drop of 86.15% [1]. - Meizhong Jiahe (美中嘉和) follows with a stock price of HKD 3.20, down by 70.91% [1]. - Another significant decline is seen in Yimeng Sunshine (一昧阳光), which has a stock price of HKD 17.00, down by 76.06% [1]. Group 3: Market Capitalization - Fosun Pharma (复星医药) has the highest market capitalization at HKD 680.48 billion, with a stock price of HKD 25.78 [2]. - Far East Horizon (远东宏信) ranks second with a market cap of HKD 328.32 billion and a stock price of HKD 6.87 [2]. - Global Medical (环球医疗) holds a market cap of HKD 114.82 billion, with a stock price of HKD 6.07 [2].

截至月份: 2025年9月30日 狀態: 新提交 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 致：香港交易及結算所有限公司 公司名稱: 佰澤醫療集團 （根據開曼群島法律註冊成立的有限公司） 呈交日期: 2025年10月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02609 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 USD | | | 50,000 | | 增加 / 減少 (-) | | | | | | USD | | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 USD | | | ...

格隆汇9月26日丨佰泽医疗(02609.HK)公告，自2025年9月26日起，刘燕及杜宏伟分别已获委任为公司副 总裁及公司副总裁兼首席财务官姚乐已获委任董事会秘书。自2025年9月26日起，(i)赵永凯因个人工作 重心调整及业务发展需要主动辞去董事会主席职务；及(ii)陈昊阳已获委任为董事长。赵永凯会继续留 任为公司执行董事。 ...

佰泽医疗(02609)发布公告，自2025年9月26日起，刘燕女士及杜宏伟博士分别已获委任为公司副总裁及 公司副总裁兼首席财务官姚乐先生已获委任董事会秘书。 自2025年9月26日起，(i)赵永凯先生已辞去提名委员会主席职务;(ii)陈昊阳博士已获委任为提名委员会主 席;(iii)赵先生已辞去薪酬委员会成员职务;(iv)陈博士已获委任为薪酬委员会成员。 自2025年9月26日起，(i)赵先生因个人工作重心调整及业务发展需要主动辞去董事会主席职务;及(ii)陈博 士已获委任为董事长。赵先生会继续留任为公司执行董事。 ...

自2025年9月26日起，(i)赵永凯先生已辞去提名委员会主席职务;(ii)陈昊阳博士已获委任为提名委员会主 席;(iii)赵先生已辞去薪酬委员会成员职务;(iv)陈博士已获委任为薪酬委员会成员。 自2025年9月26日起，(i)赵先生因个人工作重心调整及业务发展需要主动辞去董事会主席职务;及(ii)陈博 士已获委任为董事长。赵先生会继续留任为公司执行董事。 智通财经APP讯，佰泽医疗(02609)发布公告，自2025年9月26日起，刘燕女士及杜宏伟博士分别已获委 任为公司副总裁及公司副总裁兼首席财务官姚乐先生已获委任董事会秘书。 ...